Research analysts covering Apollomics.
Recent press releases and 8-K filings for APLM.
Apollomics Announces First Half 2025 Financial Results and Recent Strategic Developments
APLM
Earnings
Management Change
Legal Proceedings
- Apollomics Inc. reported a net loss of $(12.5) million for the first half of 2025, an improvement from $(35.2) million in the first half of 2024, and generated $8.5 million in revenue from a licensing agreement.
- As of June 30, 2025, the company held $2.1 million in cash, leading management to conclude there is substantial doubt about its ability to continue as a going concern within one year.
- In September 2025, Apollomics secured $4.1 million through a private placement, appointed a new management team including Mr. Howard Chen as Chairman and CEO, and reversed its wind-up plans after significant layoffs in August 2025.
- The company settled the Cayman Litigation for $5.0 million plus approximately $0.9 million in legal expenses in November 2025, resolving a claim originally valued at approximately $40 million.
Dec 22, 2025, 9:30 PM
Apollomics Inc. Announces Settlement of Cayman Litigation
APLM
Legal Proceedings
- Apollomics Inc. (APLM) announced on November 19, 2025, that it has entered into a settlement agreement to fully resolve legal proceedings in the Grand Court of the Cayman Islands.
- The litigation involved claims by two minority investors, TWVC, who had sought approximately US$40 million in damages related to the redemption of preferred shares prior to the company's 2023 merger.
- Under the terms of the agreement, Apollomics will pay TWVC a total of US$5 million in cash in installments over two years, along with approximately US$879,757.78 in associated legal expenses.
Nov 19, 2025, 9:05 PM
Apollomics Announces Auditor Change and Continued Nasdaq Listing
APLM
Auditor Change
Delisting/Listing Issues
- Apollomics Inc. changed its independent registered public accounting firm on October 13, 2025, dismissing Grant Thornton LLP and appointing Marcum Asia CPAs LLP as its replacement, effective immediately.
- On October 14, 2025, Nasdaq determined that Apollomics Inc. is in compliance with its continued listing requirements, leading to the cancellation of an appeal hearing and ensuring the company's securities will remain listed on The Nasdaq Stock Market.
Oct 16, 2025, 12:24 AM
Apollomics Inc. Reverses Wind-Up Plans and Commits to APL-101 Clinical Trials
APLM
Management Change
New Projects/Investments
Guidance Update
- Apollomics Inc. has reversed its previously announced wind-up plans and will continue clinical trial activities for APL-101 (vebreltinib).
- This decision follows the receipt of $4.1 million PIPE investments on September 3, 2025, and the appointment of a new board of directors and management team.
- The new management team includes Hung-wen (Howard) Chen as Chief Executive Officer, Yi-kuei (Alex) Chen as Chief Operating Officer, and Peter Lin as Chief Financial Officer.
- The company is committed to the ongoing global multi-country, multi-center SPARTA clinical trial of APL-101 (vebreltinib) and aims to complete these trials.
- Apollomics currently has 12 full-time employees and expects to reach 15 by October 31, 2025, with plans to re-allocate headcount to the U.S. and Taiwan.
Oct 14, 2025, 7:30 PM
Apollomics Appeals Nasdaq Delisting Notification
APLM
Delisting/Listing Issues
Legal Proceedings
Board Change
- Apollomics Inc. received a Nasdaq delisting notification on September 18, 2025, based on the Staff's belief that the company is a "public shell".
- The company disagrees with this determination and filed an appeal on September 23, 2025, which will stay the delisting pending a Nasdaq Hearings Panel decision.
- On September 12, 2025, the Grand Court of the Cayman Islands issued a consent order to stay all further proceedings in the Cayman Litigation, which was initiated on July 22, 2024.
- Following a $4.1 million private placement and the appointment of a new board on September 3, 2025, Apollomics reversed its prior wind-up plans and is now continuing operations and expanding its vebreltinib program.
Sep 25, 2025, 9:01 PM
Apollomics completes PIPE financing and reconstitutes board
APLM
Board Change
Management Change
- Apollomics Inc. completed a private placement (PIPE) on September 3, 2025, raising $4.1 million in gross proceeds by issuing 1.04 million Class A ordinary shares at $3.9317 per share.
- The company stated it was in need of immediate and urgent financing to support ongoing operations and meet current financial obligations.
- Following the PIPE, Hung-Wen (Howard) Chen, who was appointed Chairman of the Board, and his affiliates beneficially own approximately 42% of the outstanding Class A ordinary shares.
- On the Closing Date, five directors resigned (Dr. Kenneth C. Carter, Wendy Hayes, Dr. Sanjeev Redkar, Glenn S. Vraniak, and Dr. Bob Lin), and four new directors were appointed (Howard Chen, Yi-Kuei Chen, Po-Jen Hsueh, and Hsien-Chu Tsai), with Howard Chen becoming Chairman.
- An extraordinary general meeting of members, previously scheduled for September 4, 2025, was cancelled due to the funding provided by the PIPE.
Sep 3, 2025, 8:05 PM
Apollomics Inc. Announces Employee Terminations, Clinical Trial Discontinuation, and Shareholder Vote on Company Winding Up
APLM
Delisting/Listing Issues
Management Change
Profit Warning
- Apollomics Inc. (APLM) announced on August 28, 2025, the termination of all U.S. employees, including the CEO and CFO, effective August 29, 2025, and the expected discontinuation of all SPARTA clinical trial activities due to its cash position.
- The company will hold an Extraordinary General Meeting of Shareholders on September 4, 2025, to seek approval for the voluntary winding up of the Company.
- The Board is recommending the winding up because the company is unable to continue operations or pay its debts and has been unable to secure additional financing.
- It is unclear whether there will be any distributions for shareholders if the winding up is approved, and the company does not expect any distributions for shareholders, warrant holders, or option holders.
Aug 28, 2025, 10:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more